IMVT logo

IMMUNOVANT INC

IMVTNASDAQ
🏆 #1122 by market capEarnings Nov 9US Equity
$29.46▲ $0.61 (+2.10%)
Pre-market · at close
🔔
Track IMVT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.1%
7d▲ 1.2%
14d▲ 7.0%
30d▼ 12.0%
ytd▲ 15.9%
1y▲ 35.9%
🏦Market Cap
$6.08B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$28.48 – $29.46
52-Week Range
$18.74 – $45.42
Volume (shares)
51,237
Avg Volume (shares)
—
Shares Outstanding
206.6M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
$7M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.81
Dividend Yield
—
Dilution (1yr)
+13.2%
IMVT logo

IMMUNOVANT INC

IMVT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$533M▲ +21.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$407M▲ +8.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
205.5M▲ +13.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$798M▼ −$197M YoY
StockOtter · stockotter.space

About IMMUNOVANT INC

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.